ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
133.367,42
0,27%
S&P 500
5.753,75
0,15%
US Dollar vs BRL
5,4436
0,10%
Bitcoin
65.816,69
0,97%
Brent Oil
70,77
-0,25%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Harpoon Therapeutics Inc (HARP)

  7. Harpoon Therapeutics Inc (HARP) Notícias

HARP

Harpoon Therapeutics (HARP)

Harpoon Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:HARP
DataHoraFonteTítuloCódigoCompanhia
11/03/202418:22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HARPHarpoon Therapeutics Inc
11/03/202410:55Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:HARPHarpoon Therapeutics Inc
11/03/202410:46Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:HARPHarpoon Therapeutics Inc
11/03/202409:47Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:HARPHarpoon Therapeutics Inc
28/02/202409:37Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:HARPHarpoon Therapeutics Inc
08/02/202409:00Edgar (US Regulatory)Form DEFM14A - Definitive proxy statement relating to merger or acquisitionNASDAQ:HARPHarpoon Therapeutics Inc
06/02/202418:15Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:HARPHarpoon Therapeutics Inc
29/01/202418:52Edgar (US Regulatory)Form PREM14A - Preliminary proxy statements relating to merger or acquisitionNASDAQ:HARPHarpoon Therapeutics Inc
10/01/202417:07PR Newswire (US)Kuehn Law Encourages AMAM, HARP, AXNX, and CPE Investors to Contact Law FirmNASDAQ:HARPHarpoon Therapeutics Inc
09/01/202408:12IH Market NewsWall Street Highlights: HPE and Juniper Networks in Negotiations, Elliott Invests $1 Billion in Match Group, and MoreNASDAQ:HARPHarpoon Therapeutics Inc
08/01/202409:30Business WireMerck to Acquire Harpoon Therapeutics, Further Diversifying Oncology PipelineNASDAQ:HARPHarpoon Therapeutics Inc
05/01/202419:04Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:HARPHarpoon Therapeutics Inc
26/12/202309:30GlobeNewswire Inc.Harpoon Therapeutics Strengthens Leadership TeamNASDAQ:HARPHarpoon Therapeutics Inc
22/12/202318:06Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:HARPHarpoon Therapeutics Inc
20/12/202302:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:HARPHarpoon Therapeutics Inc
19/12/202309:30GlobeNewswire Inc.Harpoon Therapeutics Abstract for HPN328 Accepted for Rapid Oral Presentation at the 2024 American Society of Clinical Oncology Genitourinary Cancers SymposiumNASDAQ:HARPHarpoon Therapeutics Inc
11/12/202322:15GlobeNewswire Inc.Harpoon Therapeutics Presents HPN217 Phase 1 Clinical Data in Relapsed/Refractory Multiple Myeloma (RRMM) at ASH 2023 and Announces Selection of Recommended Phase 2 Dose (RP2D)NASDAQ:HARPHarpoon Therapeutics Inc
08/12/202318:08Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:HARPHarpoon Therapeutics Inc
24/11/202316:01Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:HARPHarpoon Therapeutics Inc
09/11/202318:28Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:HARPHarpoon Therapeutics Inc
09/11/202318:01GlobeNewswire Inc.Harpoon Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:HARPHarpoon Therapeutics Inc
03/11/202317:05Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:HARPHarpoon Therapeutics Inc
02/11/202310:15GlobeNewswire Inc.Harpoon Therapeutics Abstract for HPN217 Accepted for Presentation at the 65th American Society of Hematology (ASH) Annual Meeting and ExpositionNASDAQ:HARPHarpoon Therapeutics Inc
23/10/202308:17GlobeNewswire Inc.Harpoon Therapeutics Announces Up to $150 Million Private PlacementNASDAQ:HARPHarpoon Therapeutics Inc
21/10/202312:31GlobeNewswire Inc.Harpoon Therapeutics Announces Updated Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023NASDAQ:HARPHarpoon Therapeutics Inc
16/10/202317:05GlobeNewswire Inc.Harpoon Therapeutics to Host Webcast Reviewing HPN328 Interim Data Presented at ESMO Congress 2023 on October 23, 2023NASDAQ:HARPHarpoon Therapeutics Inc
09/10/202317:17GlobeNewswire Inc.Harpoon Therapeutics to Present Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023NASDAQ:HARPHarpoon Therapeutics Inc
28/09/202304:00GlobeNewswire Inc.Harpoon Therapeutics Presents HPN217 Interim Phase 1 Data at the IMS Annual MeetingNASDAQ:HARPHarpoon Therapeutics Inc
15/09/202308:15GlobeNewswire Inc.Harpoon Therapeutics Announces First Patients with Small Cell Lung Cancer Dosed in HPN328 Combination CohortNASDAQ:HARPHarpoon Therapeutics Inc
13/09/202318:12Dow Jones NewsHarpoon Shares Drop 7.3% as AbbVie Declines License OptionNASDAQ:HARPHarpoon Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:HARP

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
PRIO3
PETRORIO ON
BOV
AZEV4
AZEVEDO PN
BOV
PDGR3
PDG REALT ON
BOV
AMBP3
Ambipar Participacoes e ... ON
BOV
HAGA3
HAGA ON
BOV
RCSL3
RECRUSUL ON
BOV
AZEV3
AZEVEDO ON
BOV
CBEE3
AMPLA ENERG ON
BOV
BHIA3
Grupo Casas Bahia ON
BOV
TELB4
TELEBRAS PN
BOV
GFSA3
GAFISA ON
BOV
RNEW4
RENOVA PN
BOV
TCSA3
TECNISA ON
BOV
KRSA3
Kora Saude Participacoes... ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados